Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > BioAlliance Pharma Publishes Its 2008 Financial Calendar and Announces the Opening of Its European Corporate Headquarters

Abstract:
BioAlliance Pharma SA (PARIS:BIO) (Euronext Paris - ticker code BIO) has announced its financial calendar for 2008, which notably includes the publication dates for its revenue statements and half-year & annual accounts, as well as the date of its shareholders' Annual General Meeting:

BioAlliance Pharma Publishes Its 2008 Financial Calendar and Announces the Opening of Its European Corporate Headquarters

PARIS, France | Posted on January 21st, 2008

* January 31 2008 : Publication of the revenue statement for Q4 2007
* February 29 2008 : Publication of the consolidated accounts for 2007. SFAF analyst meeting at the Palais Brongniart
* April 11 2008 : Publication of the French "Document de Référence" for 2007
* April 29 2008 : Annual General Meeting at the Maison de la Chimie
* April 30 2008 : Publication of the revenue statement for Q1 2008
* July 21 2008 : Publication of the revenue statement for Q2 2008
* August 28 2008 : Publication of the consolidated half-year accounts as of June 30 2008. SFAF analyst meeting at the Maison de la Chimie
* October 30 2008 : Publication of the revenue statement for Q3 2008
* January 2009 : Publication of the revenue statement for Q4 2008

Along with other corporate information on BioAlliance Pharma S.A., a regularly updated "investor relations" section is available on the company's website (www.bioalliancepharma.com).

Furthermore, in Q1 2008, BioAlliance Pharma will present its corporate communication program for shareholders and the financial community as a whole.

BioAlliance Pharma expands and is set to open its European corporate headquarters.

BioAlliance Pharma will move into new premises in February 2008.

The new corporate headquarters (located at 49, boulevard du Général Martial Valin, in Paris' 15th Arrondissement - just down the street from its current offices) will more than double the available floor space and will enable the company to bring together its entire staff onto a single site.

"The opening of our European corporate HQ represents another important milestone and testifies to our commitment to pursuing growth whilst keeping costs under control. We are going to boost our international performance levels, notably by integrating our Development, Regulatory Affairs and Sales & Marketing teams. This is a strategic choice for progressing our product portfolio, at a time when Loramyc® is being launched on the French market and has already been granted marketing approval in other European countries, in line with our stated objectives", commented Dominique Costantini, CEO.

####

About BioAlliance Pharma SA
BioAlliance Pharma SA is a specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV. The company develops and commercializes innovative products which address resistance issues. The company has launched its first portfolio product (Loramyc®) in France and the compound is currently in Phase III clinical development in oropharyngeal candidiasis in the USA. In addition, two other innovative products are currently in Phase III clinical trials: acyclovir Lauriad® in oral herpes (based on the same Lauriad® muco-adhesive technology as Loramyc®, which enables targeted release at the disease site) and doxorubicin Transdrug® in primary liver cancer (based on the Transdrug® nanoparticle technology, designed specifically for intracellular targeting of resistant cells). The company is also developing a new therapeutic entities program focused on the oncology and infectious disease markets.

In 2007, the company has established strategic alliances for commercializing Loramyc® in Europe (with JV SpeBio) and the USA (with Par Pharmaceutical). For more information, visit BioAlliance Pharma's website at www.bioalliancepharma.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the reference document approved by the AMF on April 6th 2007 under the number R. 07-031, which is available on the AMF website (www.amf-france.org) or on BioAlliance Pharma S.A.'s website (www.bioalliancepharma.com).

For more information, please click here

Contacts:
BioAlliance Pharma SA
Dominique Costantini
President and CEO
Tel.: +33 1 45 58 76 01

or
ALIZE RP
Caroline Carmagnol
Tel.: +33 6 64 18 99 59

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Haydale Secures Exclusive Development and Supply Agreement with Tantec A/S: New reactors to be built and commissioned by Tantec A/S represent another step forward towards the commercialisation of graphene October 24th, 2014

QuantumWise guides the semiconductor industry towards the atomic scale October 24th, 2014

MEMS & Sensors Technology Showcase: Finalists Announced for MEMS Executive Congress US 2014 October 23rd, 2014

Nanoparticle technology triples the production of biogas October 23rd, 2014

Openings/New facilities/Groundbreaking/Expansion

HP Supercomputer at NREL Garners Top Honor October 19th, 2014

Graphenea opens US branch October 16th, 2014

Raytheon, UMass Lowell open on-campus research institute: Industry leader’s researchers to collaborate with faculty, students to move key technologies forward through first-of-its-kind partnership October 11th, 2014

Yale University and Leica Microsystems Partner to Establish Microscopy Center of Excellence: Yale Welcomes Scientists to Participate in Core Facility Opening and Super- Resolution Workshops October 20 Through 31, 2014 September 30th, 2014

Nanomedicine

NYU Researchers Break Nano Barrier to Engineer the First Protein Microfiber October 23rd, 2014

Iranian Scientists Apply Nanotechnology to Produce Surgery Suture October 23rd, 2014

RF Heating of Magnetic Nanoparticles Improves the Thawing of Cryopreserved Biomaterials October 23rd, 2014

Sopping up proteins with thermosponges: Researchers develop novel nanoparticle platform that proves effective in delivering protein-based drugs October 22nd, 2014

Announcements

Haydale Secures Exclusive Development and Supply Agreement with Tantec A/S: New reactors to be built and commissioned by Tantec A/S represent another step forward towards the commercialisation of graphene October 24th, 2014

QuantumWise guides the semiconductor industry towards the atomic scale October 24th, 2014

Advancing thin film research with nanostructured AZO: Innovnano’s unique and cost-effective AZO sputtering targets for the production of transparent conducting oxides October 23rd, 2014

Strengthening thin-film bonds with ultrafast data collection October 23rd, 2014

Financial Reports

Aspen Aerogels, Inc. Schedules Third Quarter 2014 Earnings Release and Conference Call for November 6, 2014 October 17th, 2014

Nanometrics to Announce Third Quarter Financial Results on October 28, 2014 October 8th, 2014

Harris & Harris Group Letter to Shareholders on Website August 19th, 2014

Arrowhead Reports Fiscal 2014 Third Quarter Financial Results and Provides Update on ARC-520 August 12th, 2014

NanoNews-Digest
The latest news from around the world, FREE





  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE